Inogen’s (INGN) Hold Rating Reaffirmed at Needham & Company LLC

Inogen (NASDAQ:INGN)‘s stock had its “hold” rating reaffirmed by research analysts at Needham & Company LLC in a research note issued to investors on Wednesday,Benzinga reports.

Separately, StockNews.com raised Inogen from a “hold” rating to a “buy” rating in a research report on Monday, February 10th.

Inogen Stock Down 2.0 %

Inogen stock opened at $7.95 on Wednesday. Inogen has a 52 week low of $5.82 and a 52 week high of $13.33. The company’s 50 day moving average price is $10.19 and its two-hundred day moving average price is $10.25. The stock has a market cap of $189.35 million, a P/E ratio of -3.53 and a beta of 1.02.

Institutional Trading of Inogen

Hedge funds have recently added to or reduced their stakes in the stock. PharVision Advisers LLC purchased a new stake in shares of Inogen during the 4th quarter worth approximately $173,000. Squarepoint Ops LLC bought a new position in Inogen during the fourth quarter valued at $424,000. State of Wyoming increased its position in Inogen by 520.3% in the fourth quarter. State of Wyoming now owns 20,229 shares of the medical technology company’s stock worth $186,000 after buying an additional 16,968 shares during the last quarter. Millennium Management LLC raised its stake in shares of Inogen by 162.5% in the fourth quarter. Millennium Management LLC now owns 143,653 shares of the medical technology company’s stock valued at $1,317,000 after buying an additional 88,924 shares during the period. Finally, Jacobs Levy Equity Management Inc. lifted its position in shares of Inogen by 4.4% during the 4th quarter. Jacobs Levy Equity Management Inc. now owns 303,522 shares of the medical technology company’s stock valued at $2,783,000 after buying an additional 12,654 shares during the last quarter. Institutional investors own 89.94% of the company’s stock.

About Inogen

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.